雷帕黴菌(Rapamycin)| Romidepsin (FK228, depsipeptide) | Daptomycin | G-418 (80 S 核醣體延伸抑制劑)
雷帕黴菌(Rapamycin) | CAS#53123-88-9 APExBIO貨號A8167
Original antifungal antibiotic
雷帕黴菌(Rapamycin)作為一種原始的抗真菌抗生素,由吸水鏈黴菌(Streptomyces hygroscopicus)生產。由於其免疫抑制作用(immunosuppressive effect),現已用於預防移植排斥反應。它還表現出對幾種可移植腫瘤(transplantable tumors)的活性和對白血病無活性(inactive against leukemias)具輕微活性。雷帕黴菌(Rapamycin)的免疫抑制作用是通過抑制T細胞的活化(activation)和增殖(proliferation)來發揮的。雷帕黴菌(Rapamycin)與 FK 結合蛋白 12 (FKBP12) 結合併形成雷帕黴素-FKBP12 複合物(rapamycin-FKBP12 complex),該複合物調節一種在細胞週期(cell cycle)進程中起重要作用的酶。Rapamycin was used as a kind of original antifungal antibiotic, which is produced by Streptomyces hygroscopicus. Now it has been used in the prevention of transplant rejection because of its immunosuppressive effect. It also exhibits activity against several transplantable tumors and slightly activity to inactive against leukemias. The immunosuppressive effect of Rapamycin is exerted by inhibiting the activation and proliferation of T cells. Rapamycin binds to FK-binding protein 12 (FKBP12) and forms the rapamycin-FKBP12 complex, which regulates an enzyme that plays an important role in the progression of the cell cycle.
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MS (Mass Spectrometry)
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Physical Appearance | A solid |
Storage | Desiccate at -20°C |
M.Wt | 914.18 |
Cas No. | 53123-88-9 |
Formula | C51H79NO13 |
Synonyms | Sirolimus,(-)-Rapamycin, AY-22989, WY-090217, Antibiotic AY22989 |
Solubility | ≥45.7 mg/mL in DMSO; insoluble in H2O; ≥58.9 mg/mL in EtOH with ultrasonic |
SDF | Download SDF |
Canonical SMILES | O[C@H]1[C@H](OC)C[C@H](C[C@@H](C)[C@H](CC([C@H](C)/C=C(C)/[C@H]([C@@H](OC)C([C@@H](C[C@@H](/C=C/C=C/C=C(C)/[C@@H](OC)C[C@@H]2CC[C@@H](C)[C@@](C(C(N3[C@H]4CCCC3)=O)=O)(O)O2)C)C)=O)O)=O)OC4=O)CC1 |
Shipping Condition | Ship with blue ice, or upon other requests. |
General tips | For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. We do not recommend long-term storage for the solution, please use it up soon. |
- 1. Jialin He, Jianyang Liu, et al. "OM-MSCs Alleviate the Golgi Apparatus Stress Response following Cerebral Ischemia/Reperfusion Injury via the PEDF-PI3K/Akt/mTOR Signaling Pathway." Oxid Med Cell Longev. 2021 Nov 13;2021:4805040. PMID:34815829
- 2. Fang Wang, Jing Zhang, et al. "2-Deoxy-D-glucose impedes T cell-induced apoptosis of keratinocytes in oral lichen planus." J Cell Mol Med. 2021 Nov;25(21):10257-10267. PMID:34672419
- 3. Na Li, Ming Yan. "Extracellular IL-37 promotes osteogenic and odontogenic differentiation of human dental pulp stem cells via autophagy." Exp Cell Res. 2021 Oct 1;407(1):112780. PMID:34411610
- 4. Yuhui Yang, Yiping Huang, et al. "Compressive force regulates cementoblast migration via downregulation of autophagy." J Periodontol. 2021 Nov;92(11):128-138. PMID:34231875
- 5. Xiaoli Liu, Yan Gu, et al. "Honokiol induces paraptosis-like cell death of acute promyelocytic leukemia via mTOR & MAPK signaling pathways activation." Apoptosis. 2021 Apr;26(3-4):195-208. PMID:33550458
- 6. Weiwen Wang, Yan Zhang, et al. "CXCR4 induces cell autophagy and maintains EBV latent infection in EBVaGC." Theranostics. 2020 Sep 18;10(25):11549-11561. PMID:33052232
- 6. Weiwen Wang, Yan Zhang, et al. "CXCR4 induces cell autophagy and maintains EBV latent infection in EBVaGC." Theranostics. 2020 Sep 18;10(25):11549-11561. PMID:33052232
- 7. Liu Y, Li J, et al. "Advanced glycation end-products suppress autophagy by AMPK/mTOR signaling pathway to promote vascular calcification." Mol Cell Biochem. 2020;471(1-2):91-100. PMID:32514882
- 8. Wang J, Chen Y, et al. "mTORC1-IRE1α pathway activation contributes to palmitate-elicited triglyceride secretion and cell death in hepatocytes." Exp Biol Med (Maywood). 2020;1535370220928276. PMID:32436749
- 9. Meng XL, Fu P, et al. "Increased EZH2 Levels in Anterior Cingulate Cortex Microglia Aggravate Neuropathic Pain by Inhibiting Autophagy Following Brachial Plexus Avulsion in Rats." Neurosci Bull. 2020;10.1007/s12264-020-00502-w. PMID:32346844
- 10. Xie X, Yang C, et al. "Advanced glycation end products reduce macrophage-mediated killing of Staphylococcus aureus by ARL8 upregulation and inhibition of autolysosome formation." Eur J Immunol. 2020;10.1002/eji.201948477. PMID:32250445
- 11. Wang F, Zhang J, et al. "The mTOR-glycolytic pathway promotes T-cell immunobiology in oral lichen planus." Immunobiology. 2020;225(3):151933. PMID:32201095
- 12. Zhao F, Wang J, et al. "Neuroprotection by Walnut-derived Peptides through Autophagy Promotion via Akt/mTOR Signaling Pathway against Oxidative Stress in PC12 Cells." J Agric Food Chem. 2020;10.1021/acs.jafc.9b08252. PMID:32090563
- 13. Xuyang Zhao, Yadong Ma, et al. "mTORC2 mediate FLCN-induced HIF2α nuclear import and proliferation of clear cell renal cell carcinoma." bioRxiv. 2020 January 13.
- 14. Mitchell DC, Menon A, et al. "Cyclin-dependent kinase 4 inhibits the translational repressor 4E-BP1 to promote cap-dependent translation during mitosis-G1 transition." FEBS Lett. 2020 Apr;594(8):1307-1318. PMID:31853978
- 15. WandaNowaka, Leandro NicolásGrendasa, et al. "Pro-inflammatory monocyte profile in patients with major depressive disorder and suicide behaviour and how ketamine induces anti-inflammatory M2 macrophages by NMDAR and mTOR." EBioMedicine. Available online 18 November 2019.
- 16. Liu XH, Liang S, et al. "Metabolomics Analysis Identifies Sphingolipids as Key Signaling Moieties in Appressorium Morphogenesis and Function in Magnaporthe oryzae." MBio. 2019 Aug 20;10(4). pii: e01467-19. PMID:31431550
- 17. Zhang C, Duan Y, et al. "TFEB mediates immune evasion and resistance to mTOR inhibition of renal cell carcinoma via induction of PD-L1." Clin Cancer Res. 2019 Aug 5. pii: clincanres.0733.2019. PMID:31383732
- 18. Li CF, Pan YK, et al. "Autophagy protects HUVECs against ER stress-mediated apoptosis under simulated microgravity." Apoptosis. 2019 Jul 29. PMID:31359205
- 19. Ye J, Xue M, et al. "Diosbulbin B-Induced Mitochondria-Dependent Apoptosis in L-02 Hepatocytes is Regulated by Reactive Oxygen Species-Mediated Autophagy." Front Pharmacol. 2019 Jun 19;10:676. PMID:31275148
- 20. Wang Z, Zhang Z, et al. "Polysaccharides from Enteromorpha Prolifera Ameliorate Acute Myocardial Infarction in Vitro and in Vivo via Up-Regulating HIF-1α." Int Heart J. 2019 Jun 28. PMID:31257333
- 21. Tang RH, Qi RQ, et al. "Interleukin-4 affects microglial autophagic flux." Neural Regen Res. 2019 Sep;14(9):1594-1602. PMID:31089059
- 22. Yang D, Zhang B, et al. "COPS5 negatively regulates goat endometrial function via the ERN1 and mTOR-autophagy pathways during early pregnancy." J Cell Physiol. 2019 Aug;234(10):18666-18678. PMID:30927262
- 23. Zhang M, Liu F, et al. "The MTOR signaling pathway regulates macrophage differentiation from mouse myeloid progenitors by inhibiting autophagy." Autophagy. 2019 Feb 27:1-13. PMID:30724690
- 24. Rossi A, Pakhomova ON, et al. "Mechanisms and immunogenicity of nsPEF-induced cell death in B16F10 melanoma tumors." Sci Rep. 2019 Jan 23;9(1):431. PMID:30674926
- 25. Benjamin Cook. "Investigating Autophagy, Extracellular Vesicles, and Glycobiology." Loyola University Chicago.2018.
- 26. Yang D, Jiang T, et al."CREB3 Regulatory Factor -mTOR-autophagy regulates goat endometrial function during early pregnancy." Biol Reprod. 2018 Feb 13. PMID:29447354
- 27. Aluru M, McKinney T, et al. "Mitogen-activated protein kinases, Fus3 and Kss1, regulate chronological lifespan in yeast." Aging (Albany NY). 2017 Dec 21;9(12):2587-2609. PMID:29273704
- 28. Yang D, Jiang T, et al. "Hormone regulates endometrial function via cooperation of endoplasmic reticulum stress and mTOR-autophagy." J Cell Physiol. 2017 Dec 5. PMID:29206294
- 29. Marsh KM, Schipper D, et al. "Metabolic Impact of Rapamycin (Sirolimus) and B-Estradiol Using Mouse Embryonic Fibroblasts as a Model for Lymphangioleiomyomatosis." Lung. 2017 Jun 2. PMID:28577037
- 30. Zhixia Qiu , Shuihong Zhang , et al. "The role of curcumin in disruption of HIF-1α accumulation to alleviate adipose fibrosis via AMPK-mediated mTOR pathway in high-fat diet fed mice." J Funct Foods. 2017 Mar.
- 31. Li X, Guo K, et al. "5-HT 2 receptor mediates high-fat diet-induced hepatic steatosis and very low density lipoprotein overproduction in rats." Obes Res Clin Pract. 2018 Jan - Feb;12(1S1):16-28. PMID:27133527
- 32. Holubova, Kristina, et al. "Rapamycin blocks the antidepressant effect of ketamine in task-dependent manner." Psychopharmacology (2016): 1-21. PMID:27004790
- 33. Hagg A, Colgan TD, et al. "Using AAV vectors expressing the β2-adrenoceptor or associated Gα proteins to modulate skeletal muscle mass and muscle fibre size." Sci Rep. 2016 Mar 4;6:23042. PMID:26972746
- 34. Fu J, Ma S, et al. "Long-term Stress with Hyperglucocorticoidemia-induced Hepatic Steatosis with VLDL Overproduction Is Dependent on both 5-HT2 Receptor and 5-HT Synthesis in Liver." Int J Biol Sci. 2016 Jan 1;12(2):219-34. PMID:26884719
- 35. Ranjan, Kishu, and Chandramani Pathak. "Expression of cFLIPL Determines the Basal Interaction of Bcl‐2 with Beclin‐1 and Regulates p53 Dependent Ubiquitination of Beclin‐1 During Autophagic Stress." Journal of cellular biochemistry (2015). PMID:26682748
- 36. Deng, Jiangshan, et al. "Identification of the protective role of DJ-1 in hypoglycemic astrocyte injury using proteomics." Journal of proteome research (2015). PMID:26057206
APExBIO提供優質的胜肽和生物分析試劑,廣泛產品線如Protease、Chromatin/Epigenetics表觀遺傳學、MAPK Signal、DNA Damege/DNA repair、細胞凋亡、腫瘤生物學、Stem cell等研究領域, 還提供定制的服務,包括多肽合成,抗體的生產和檢測的發展。產品線DNA/RNA prep kit、Drug Screening panel、Bioactive peptides、Growth factors、Biotinylation Reagents、tag peptides、amino Acids、Growth factors等。APExBIO產品質量都伴隨著證書的分析,高效液相色譜,質譜,和HMNR數據。
A3173 | AMD-070 | 558447-26-0 | 98.00% | CXCR4 antagonist,potent and selective |
A3174 | AMD-070 hydrochloride | 880549-30-4 | 98.00% | CXCR4 antagonist,potent and selective |
A3176 | Ampalex | 154235-83-3 | 98.54% | Ampakine and nootropic |
A3177 | AN-2690 | 174671-46-6 | 98.60% | Antifungal agent |
A3178 | AN-2728 | 906673-24-3 | 99.33% | PDE4 inhibitor,anti-inflammatory compound |
A3179 | Anamorelin | 249921-19-5 | 99.68% | Ghrelin receptor agonist, synthetic, orally active |
A3182 | Anguizole | 442666-98-0 | 98.00% | Inhibitor of HCV replication |
A3184 | AR-A014418 | 487021-52-3 | 98.34% | GSK3β inhibitor, ATP-competitive and selective |
A3185 | AR-C155858 | 496791-37-8 | 99.52% | MCT1 and MCT2 inhibitor |
A3188 | ARRY-520 R enantiomer | 885060-08-2 | 98.00% | KSP inhibitor |
A3189 | AS 602801 | 848344-36-5 | 98.72% | Jun Kinase Inhibitor |
A3190 | ASC-J9 | 52328-98-0 | 98.00% | AR degradation enhancer,antiumor agent |
A3191 | Ascomycin(FK 520) | 104987-12-4 | 98.00% | Macrolide immunosuppressant,FK-520 analog |
A3192 | Asenapine hydrochloride | 1412458-61-7 | 98.00% | Atypical antipsychotic |
A3193 | ASP3026 | 1097917-15-1 | 99.38% | ALK inhibitor,potent and selective |
A3194 | AST 487 | 630124-46-8 | 99.29% | RET kinase inhibitor |
A3195 | Asunaprevir (BMS-650032) | 630420-16-5 | 99.80% | NS3 protease inhibitor |
A3196 | AT-101 | 90141-22-3 | 98.00% | BH3-mimetic,gossypol enantiomer |
A3197 | AT7519 Hydrochloride | 902135-91-5 | 99.80% | Multi-CDK inhibitor |
A3198 | AT7519 trifluoroacetate | 1431697-85-6 | 98.00% | CDK/cyclin inhibitor |
A3199 | AT7867 dihydrochloride | 1431697-86-7 | 98.00% | Akt1 and p70S6K/PKA inhibitor |
A3201 | Atrasentan hydrochloride | 195733-43-8 | 98.00% | Endothelin receptor antagonist |
A3202 | Avermectin B1 | 71751-41-2 | 98.00% | Insecticide |
A3206 | AVL-292 | 1202757-89-8 | 98.27% | Btk inhibitor |
A3208 | Avosentan | 290815-26-8 | 98.00% | ETA receptor antagonist |
A3209 | AXL1717 | 477-47-4 | 98.07% | IGF-1R inhibitor,orally active |
A3210 | AZ20 | 1233339-22-4 | 99.93% | ATR inhibitor,potent and selective |
A3214 | AZD1152 | 722543-31-9 | 98.78% | Aurora B kinase inhibitor,highly potent and selective |
A3215 | AZD7687 | 1166827-44-6 | 98.00% | DGAT inhibitor,potent and selective |
A3216 | Balaglitazone | 199113-98-9 | 99.62% | PPAR-γ partial agonist |
A3217 | Balapiravir | 690270-29-2 | 98.00% | Polymerase inhibitor,anti-HCV |
A3218 | BAM7 | 331244-89-4 | 98.00% | BAX activator,direct and selective |
A3219 | BAN ORL 24 | 475150-69-7 | 98.00% | NOP receptor antagonist, potent and selective |
A3220 | Bardoxolone | 218600-44-3 | 99.55% | Once-a-day treatment for CKD |
A3221 | Bardoxolone methyl | 218600-53-4 | 98.75% | IKK inhibitor, potent antioxidant inflammation modulator |
A3222 | Baricitinib phosphate | 1187595-84-1 | 99.59% | JAK1/JAK2 inhibitor |
A3227 | BAY 61-3606 | 732983-37-8 | 98.45% | Syk Inhibitor |
A3228 | BAY 61-3606 dihydrochloride | 648903-57-5 | 98.00% | Syk tyrosine kinase inhibitor |
A3230 | Bay 65-1942 HCl salt | 600734-06-3 | 98.00% | IKKβ kinase inhibitor |
A3232 | Bazedoxifene | 198481-32-2 | 98.00% | Estrogen receptor modulator |
A3236 | Benfotiamine | 22457-89-2 | 99.76% | Drug for painful nerve condition |
A3237 | Betulinic acid | 472-15-1 | 98.00% | Anti-HIV and antitumor compound,pentacyclic triterpenoid |
A3238 | BEZ235 Tosylate | 1028385-32-1 | 98.28% | MTOR/P13K inhibitor |
A3239 | B-HT 920 | 36085-73-1 | 98.00% | D2 receptor agonist |
A3240 | BIBX 1382 | 196612-93-8 | 98.00% | EGFR inhibitor,potent and selective |
A3241 | Bilobalide | 33570-04-6 | 98.00% | Neuroprotective agent |
A3242 | Bitopertin | 845614-11-1 | 99.70% | Glycine reuptake inhibitor(GlyT1) |
A3244 | Bivalirudin Trifluoroacetate | 128270-60-0 | 98.07% | Reversible thrombin inhibitor |
A3246 | BMN-673 8R,9S | 1207456-00-5 | 99.75% | Inactive form of BMN 673, used as negative control |
A3248 | BMS345541 hydrochloride | 547757-23-3 | 99.57% | IKK inhibitor,highly selective |
A3250 | BMS-509744 | 439575-02-7 | 98.00% | Itk inhibitor,potent and selective |
A3252 | BMS-599626 Hydrochloride | 873837-23-1 | 99.58% | EGFR/HER2 inhibitor,potent and selective |
A3253 | BMS-626529 | 701213-36-7 | 98.01% | HIV-1 attachment inhibitor |
A3254 | BMS-663068 | 864953-29-7 | 98.00% | HIV-1 attachment inhibitor |
A3256 | BMS-690514 | 859853-30-8 | 98.00% | HER/EGFR inhibitor |
A3257 | BMS-790052 dihydrochloride | 1009119-65-6 | 99.81% | HCV NS5A inhibitor |
A3258 | BMS-833923 | 1059734-66-5 | 99.84% | Smoothened inhibitor |
A3259 | BMS-927711 | 1289023-67-1 | 98.99% | CGRP receptor antagonist |
A3260 | BMX-IN-1 | 1431525-23-3 | 97.99% | BMX (also termed ETK) kinase inhibitor |
A3261 | Boceprevir | 394730-60-0 | 98.00% | HCV protease inhibitor,potent and selective |
A3263 | BRAF inhibitor | 918505-61-0 | 98.00% | Potent B-raf inhibitor |
A3264 | B-Raf inhibitor | 1315330-11-0 | 98.00% | A B-Raf inhibitor |
A3265 | Brassinolide | 72962-43-7 | 98.00% | Plant growth regulator |
A3266 | BS-181 | 1092443-52-1 | 98.00% | CDK7 inhibitor,highly selective |
A3268 | CAL-130 Hydrochloride | 1431697-78-7 | 98.00% | PI3K inhibitor |
A3270 | Calcifediol monohydrate | 63283-36-3 | 99.43% | Prehormone;vitamin D3 metabolite |
A3271 | Calcipotriol | 112965-21-6 | 98.00% | Vitamin D3 analog,regulates cell differentiation and proliferation |
A3275 | Calcium-Sensing Receptor Antagonists I | 478963-79-0 | 98.00% | CaSR antagonist |
A3276 | Canertinib dihydrochloride | 289499-45-2 | 99.72% | Pan-ErbB inhibitor, potent and selective |
A3277 | Capadenoson | 544417-40-5 | 98.00% | Adenosine A1 receptor agonist |
A3278 | Nonivamide (Capsaicin Analog) | 2444-46-4 | 99.53% | TRPV1 receptor agonist |
A3279 | Capsazepine | 138977-28-3 | 99.25% | TRPV1 ion channel antagonist |
A3282 | Cariprazine | 839712-12-8 | 99.19% | D2/D3 partial agonist,antipsychotic drug |
A3284 | Cathepsin S inhibitor | 1373215-15-6 | 98.33% | Blocks MHCII antigen presentation |
A3285 | CB 300919 | 289715-28-2 | 98.00% | Potential therapy for ovarian cancer |
A3286 | CB30865 | 206275-15-2 | 98.00% | Nampt inhibitor |
A3287 | CC-401 hydrochloride | 1438391-30-0 | 98.00% | JNK inhibitor |
A3288 | CC-930 | 899805-25-5 | 98.00% | JNK inhibitor,potent and selective |
A3289 | CCG-63802 | 620112-78-9 | 98.00% | RGS protein inhibitor |
A3290 | CCG-63808 | 620113-73-7 | 98.00% | Reversible RGS inhibitor |
A3291 | CCT241533 | 1262849-73-9 | 98.00% | Potent Chk2 inhibitor |
A3292 | CCT241533 hydrochloride | 1431697-96-9 | 98.00% | CHK2 kinase inhibitor, novel |
A3293 | CDK inhibitor II | 1269815-17-9 | 98.00% | CDK inhibitor |
A3294 | CDK9 inhibitor | 1415559-43-1 | 98.00% | CDK9 inhibitor |
A3295 | CDK9 inhibitor 2 | 1263369-28-3 | 98.00% | CDK9 inhibitor |
A3297 | CEP-32496 hydrochloride | 1227678-26-3 | 98.00% | B-Raf/C-Raf inhibitor,highly potent |
A3297 | CEP-32496 hydrochloride | 1227678-26-3 | 98.00% | B-Raf/C-Raf inhibitor,highly potent |
A3298 | Cetirizine | 83881-51-0 | 99.65% | Antihistamine |
A3300 | Cevimeline hydrochloride hemihydrate | 153504-70-2 | 98.00% | Agonist of muscarinic receptor (M1/M3) |
A3302 | CGI-1746 | 910232-84-7 | 98.00% | Btk inhibitor |
A3303 | CGP60474 | 164658-13-3 | 98.00% | CDKs and PKC inhibitor, potent |
A3304 | CGS 21680 | 120225-54-9 | 98.00% | Adenosine A2 receptor agonists,potent and selective |
A3305 | CHAPS | 75621-03-3 | 97.71% | Zwitterionic detergent for membrane proteins,nondenaturing |
A3306 | Chelerythrine Chloride | 3895-92-9 | 99.36% | PKC antagonist |
A3307 | CHIR-090 | 728865-23-4 | 99.37% | Potent LpxC inhibitor |
A3308 | Choline Fenofibrate | 856676-23-8 | 99.92% | Choline salt of fenofibric acid |
A3309 | CHR-6494 | 1333377-65-3 | 98.00% | Haspin inhibitor,potent ands selective |
A3310 | chroman 1 | 1273579-40-0 | 98.00% | ROCK II inhibitor, highly potent and selective |
A3311 | CID-2858522 | 758679-97-9 | 98.00% | NF-κB pathway inhibitor |
A3313 | Cinacalcet | 226256-56-0 | 99.48% | Calcimimetic agent,orally active |
A3314 | Cinaciguat | 329773-35-5 | 98.00% | Soluble guanylate cyclase (sGC) activators |
A3315 | Clemizole | 442-52-4 | 99.06% | H1 histamine receptor antagonist |
A3316 | Clemizole hydrochloride | 1163-36-6 | 99.73% | H1 histamine receptor antagonist |
A3317 | Clozapine N-oxide (CNO) | 34233-69-7 | 99.74% | Metabolite of clozapine, used in chemogenetics. |
A3319 | CMK | 821794-90-5 | 98.00% | RSK2 kinase inhibitor |
A3320 | CO-1686 (AVL-301) | 1374640-70-6 | 99.28% | EGFR inhibitor |
A3321 | Cobimetinib | 934660-93-2 | 99.71% | Selective MEK inhibitor |
A3322 | Cobimetinib (racemate) | 934662-91-6 | 98.00% | Selective MEK inhibitor |
A3331 | CP-809101 hydrochloride | 1215721-40-6 | 98.00% | 5-HT2C receptor agonist, potent and selective |
A3334 | CTS-1027 | 193022-04-7 | 98.00% | MMPs inhibitor |
A3335 | Curcumin | 458-37-7 | 98.36% | Tyrosinase inhibitor |
A3336 | CVT-313 | 199986-75-9 | 98.04% | Cdk2 inhibitor |
A3337 | CX-6258 | 1202916-90-2 | 98.28% | Pan-Pim kinases Inhibitor |
A3339 | CYT387 sulfate salt | 1056636-06-6 | 98.00% | JAK1/JAK2 inhibitor |
A3340 | CZC24832 | 1159824-67-5 | 98.00% | Selective PI3K-γ inhibitor |
A3342 | D4476 | 301836-43-1 | 99.22% | CK1/ALK5 inhibitor,specific and cell permeable |
A3343 | D609 | 83373-60-8 | 98.00% | PC-PLC inhibitor |
A3344 | D-64131 | 74588-78-6 | 98.00% | Tubulin polymerization inhibitor |
A3345 | Dabigatran etexilate mesylate | 872728-81-9 | 99.41% | Direct thrombin inhibitor,anticoagulant,prodrug of dabigatran |
A3346 | Dabigatran ethyl ester | 429658-95-7 | 98.00% | Thrombin activity inhibitor |
A3347 | Dabrafenib Mesylate (GSK-2118436) | 1195768-06-9 | 99.78% | Inhibitor of BRAF(V600) mutants |
A3348 | Daminozide | 1596-84-5 | 98.00% | KDM2A inhibitor |
A3349 | Darapladib | 356057-34-6 | 99.54% | Lp-PLA2 inhibitor, selective and orally active |
A3351 | Dasatinib hydrochloride | 854001-07-3 | 99.91% | Multi-BCR/Abl and Src kinase inhibitor, oral active |
A3352 | Daun02 | 290304-24-4 | 98.00% | Cell viability inhibitor,DNA synthisis inhibitor |
A3353 | DB07268 | 929007-72-7 | 98.84% | JNK1 inhibitor |
A3355 | Deferasirox Fe3+ chelate | 554435-83-5 | 98.00% | Oral iron chelator |
A3356 | Delafloxacin | 189279-58-1 | 99.81% | Fluoroquinolone antibiotic |
A3357 | Delafloxacin meglumine | 352458-37-8 | 98.00% | Fluoroquinolone antibiotic agent |
A3358 | Deltarasin | 1440898-61-2 | 98.00% | KRAS-PDEδ interaction inhibitor |
A3359 | Desmopressin | 16679-58-6 | 98.66% | Hemostatic and anti-diuretic |
A3360 | Desmopressin Acetate | 62288-83-9 | 98.73% | Synthetic analogue of arginine vasopressin |
A3363 | DGAT-1 inhibitor | 701232-20-4 | 99.64% | Diacylglycerol acyltransferase (DGAT1) inhibitor |
A3366 | Dipraglurant | 872363-17-2 | 98.00% | mGluR5 antagonist |
A3368 | DMAT | 749234-11-5 | 98.60% | CK2 inhibitor,potent and selective |
A3369 | DMP 777 | 157341-41-8 | 98.00% | Leukocyte elastase (HLE) inhibitor |
A3370 | Docetaxel Trihydrate | 148408-66-6 | 99.78% | Depolymerisation of microtubules inhibitor |
A3371 | Doramectin | 117704-25-3 | 97.08% | Antiparasitic antibiotic |
A3374 | Dronedarone | 141626-36-0 | 99.58% | CYP3A4 and 2D6 inhibitor,moderate |
A3375 | DY131 | 95167-41-2 | 99.82% | ERRγ agonist |
A3378 | E-3810 | 1058137-23-7 | 98.00% | VEGF/FGF dual inhibitor, potent and selective |
A3380 | Ebrotidine | 100981-43-9 | 98.00% | H2-receptor antagonist,competitive |
A3381 | Edoxaban | 480449-70-5 | 99.27% | Factor Xa inhibitor |
A3383 | Edoxaban tosylate monohydrate | 1229194-11-9 | 99.34% | Oral factor Xa inhibitor |
A3384 | Elacridar | 143664-11-3 | 98.17% | BCRP inhibitor |
A3385 | Elacridar hydrochloride | 143851-98-3 | 98.00% | BCRP and P-GP inhibitor |
A3387 | Eltrombopag Olamine | 496775-62-3 | 98.49% | C-mpl agonist |
A3389 | EMD638683 | 1181770-72-8 | 98.46% | SGK1 inhibitor |
A3392 | Emodin | 518-82-1 | 99.09% | Naturally occurring anthraquinone,antiproliferative |
A3394 | Epothilone D | 189453-10-9 | 98.00% | Natural polyketide compound |
A3395 | Ercalcidiol | 21343-40-8 | 98.00% | Vitamin D2 metabolite,ligand of VDR-like receptors |
A3396 | Ercalcitriol | 60133-18-8 | 98.00% | Active metabolite of vitamin D2 |
A3397 | Erlotinib | 183321-74-6 | 99.47% | EGFR tyrosine kinase inhibitor |
A3399 | Esomeprazole Magnesium trihydrate | 217087-09-7 | 98.32% | Proton pump inhibitor |
A3401 | Etifoxine hydrochloride | 56776-32-0 | 99.87% | GABAA receptor potentiator |
A3403 | Etofenamate | 30544-47-9 | 98.05% | Non-steroidal anti-inflammatory drug |
A3404 | Etomoxir | 124083-20-1 | 99.75% | (CPT)-1 and DGAT activity inhibitor |
A3405 | Etoricoxib | 202409-33-4 | 99.82% | Specific COX-2 inhibitor |
A3407 | EVP-6124 hydrochloride | 550999-74-1 | 99.85% | Alpha7 nAChR agonist |
A3408 | Exendin-4 | 141758-74-9 | 99.66% | GLP-1 activator |
A3411 | Faropenem daloxate | 141702-36-5 | 98.00% | Oral penem,beta-lactam antibiotic |
A3412 | Fenretinide | 65646-68-6 | 98.00% | Synthetic retinoid agonist |
A3413 | FH535 | 108409-83-2 | 99.62% | Wnt/B-catenin inhibitor |
A3415 | Firategrast | 402567-16-2 | 99.56% | α4β1/α4β7 integrin antagonist |
A3416 | FK 3311 | 116686-15-8 | 98.00% | Selective COX-2 inhibitor |
A3417 | Flavopiridol | 146426-40-6 | 99.52% | Pan-cdk inhibitor |
A3418 | Flecainide acetate | 54143-56-5 | 99.82% | Antiarrhythmic drug |
A3419 | Fluvastatin | 93957-54-1 | 98.33% | HMGCR inhibitor |
A3420 | FMK | 821794-92-7 | 98.82% | RSK inhibitor |
A3421 | Fosamprenavir Calcium Salt | 226700-81-8 | 99.71% | Prodrug of antiretroviral protease inhibitor amprenavir |
A3423 | Galanthamine | 357-70-0 | 99.12% | Acetylcholinesterase inhibitor |
A3424 | Gambogic Acid | 2752-65-0 | 98.54% | Caspase activator and apoptosis inducer |
A3429 | GANT 58 | 64048-12-0 | 99.38% | GLI antagonist,novel and potent |
A3432 | GDC-0941 dimethanesulfonate | 957054-33-0 | 99.78% | PI3K inhibitor |
A3433 | Gefitinib hydrochloride | 184475-55-6 | 99.87% | Potent EGFR inhibitor |
A3434 | Genz-644282 | 529488-28-6 | 98.00% | Non-camptothecin inhibitor of topoisomerase I |
A3435 | glucagon receptor antagonists 1 | 503559-84-0 | 98.00% | Glucagon receptor antagonist,highly potent |
A3436 | glucagon receptor antagonists 2 | 202917-18-8 | 98.00% | Glucagon receptor antagonist,highly potent |
A3437 | glucagon receptor antagonists 3 | 202917-17-7 | 98.00% | Glucagon receptor antagonist |
A3438 | Glucocorticoid receptor agonist | 1245526-82-2 | 98.00% | Glucagon receptor antagonist |
A3440 | Glyoxalase I inhibitor | 221174-33-0 | 98.00% | Glyoxalase I inhibitor |
A3441 | GPR120 modulator 1 | 1050506-75-6 | 98.00% | GPR120 modulator |
A3442 | GPR120 modulator 2 | 1050506-87-0 | 98.00% | GPR120 modulator |
A3443 | Granisetron | 109889-09-0 | 98.00% | Serotonin 5-HT3 receptor antagonist |
A3444 | GS-9620 | 1228585-88-3 | 98.01% | TLR-7 agonist |
A3445 | GSK 525768A | 1260530-25-3 | 98.00% | inactive stereoisomer of I-BET-762 |
A3446 | GSK126 | 1346574-57-9 | 98.32% | EZH2 inhibitor |
A3448 | GSK2606414 | 1337531-36-8 | 98.18% | PERK inhibitor,potent and selective |
A3449 | GSK343 | 1346704-33-3 | 98.95% | EZH2 inhibitor,potent,selective and cell permeable |
A3450 | GSK-923295 | 1088965-37-0 | 98.28% | CENP-E inhibitor,small-molecule |
A3451 | Guanfacine hydrochloride | 29110-48-3 | 99.41% | α2A-adrenoceptor agonist |
A3452 | GW-1100 | 306974-70-9 | 98.00% | GPR40 antagonist |
A3453 | GW1929 | 196808-24-9 | 98.00% | Potent PPARγ agonist |
A3454 | GW3965 | 405911-09-3 | 98.00% | HLXRα/hLXRβ agonist,potent and selective |
A3456 | GW843682X | 660868-91-7 | 98.00% | PLK1/PLK3 inhibitor,potent and selective |
A3460 | HhAntag | 496794-70-8 | 98.95% | GLI1-mediated transcription inhibitor |
A3461 | HIV-1 integrase inhibitor | 544467-07-4 | 98.00% | Uesful for anti-HIV |
A3465 | HOE 33187 | 23623-08-7 | 98.00% | Blue fluorescent dyes |
A3466 | Hoechst 33258 | 23491-45-4 | 99.88% | Blue fluorescent dyes |
A3472 | Hoechst 33342 | 875756-97-1 | 98.84% | Blue fluorescent dyes |
留言列表